RxDoctor Payments Data

Brianah Doeden, APRN

Family · Auburn, KYNPI 1841211356

Payments from drug & device makers

$699in general payments, 2019–2025

Across 34 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$180
  • AbbVie$151
  • Pfizer$91
  • Novo Nordisk$70
  • Lilly USA, LLC$58
  • Corcept Therapeutics$32
  • plus $116 from 7 others

What the payments were for

  • Food & beverage$699100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$699 in reported general payments places this provider in the 55th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$16,903
Medicare patients
100
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$30,456
FarxigaDapagliflozin Propanediol15$17,516
JardianceEmpagliflozin11$16,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,037
Albuterol Sulfate HfaAlbuterol Sulfate61$1,853
Pantoprazole Sodium76$960
SynthroidLevothyroxine Sodium14$798
Atorvastatin Calcium132$633
Quetiapine Fumarate11$605
Citalopram HbrCitalopram Hydrobromide45$515
Potassium Chloride35$441
Duloxetine Hcl31$415
Gabapentin42$404
Tamsulosin Hcl24$375
Levothyroxine Sodium53$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$70$30,45628 claims
AstraZenecaFarxiga$180$17,51615 claims
GSKTrelegy Ellipta$14$13,03714 claims
AbbVieSynthroid$151$79814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,374 family providers in Kentucky.

Other family in Auburn

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →